BioNTech Shuts Three German Manufacturing Sites by 2028
BioNTech is closing three of its German manufacturing sites in stages by the end of 2028 after failing to find a buyer for the facilities. The Mainz-based biotechnology firm has arranged for Pfizer, its long-standing vaccine partner, to take over production of their Covid-19 shot. The handover effectively ends BioNTech’s role as a large-scale vaccine manufacturer in its home country, reversing the rapid expansion drive the company undertook only a few years ago.
Wind-Down Timeline and Staff Impacts Across Three Facilities
The manufacturing wind-down begins in Tübingen at the close of 2027, followed by Marburg in early 2028, and Idar-Oberstein at the end of 2028. Approximately 1,800 staff members across the three locations are affected by the closures, including roughly 440 workers stationed at Idar-Oberstein alone. Local leaders have responded sharply to the restructuring plans. Tübingen Mayor Boris Palmer called the closure plans alarming, while the works council in Idar-Oberstein reported a severe loss of trust in company management.
Founders Plan New Venture Amid Patent Lawsuits
As the plant closures proceed, Uğur Şahin and Özlem Türeci plan to establish a separate venture named Arife SE. The new entity is independent and not a BioNTech project, though people familiar with the matter indicate friction regarding patents, future financing, and staff transfers. Meanwhile, a federal judge in Delaware denied motions from BioNTech, Pfizer, and Moderna to dismiss patent-infringement lawsuits brought by Monsanto, a subsidiary of Bayer. The ruling allows the plaintiffs to advance their case in court, raising questions for investors about how intellectual property will be divided.
Cancer Pipeline Advances as BioNTech Shifts Focus
Offsetting the operational retreat, BioNTech’s clinical pipeline advances through its shift toward oncology. The company and partner OncoC4 released updated Phase 3 results from the PRESERVE-003 trial evaluating gotistobart in previously treated squamous non-small cell lung cancer, where median overall survival reached 18.5 months compared to 10.0 months on standard chemotherapy. BioNTech closed Friday at EUR 86.10, bringing its market capitalisation to EUR 21.60 billion as the firm trades its pandemic-era manufacturing footprint for a focused identity as a cancer specialist.
Frequently Asked Questions About BioNTech Plant Closures
How many employees are affected by the BioNTech plant closures?
Roughly 1,800 staff members across the Tübingen, Marburg, and Idar-Oberstein facilities are affected by the phased wind-down, which concludes at the end of 2028.
Who will take over Covid-19 vaccine production in Germany?
Pfizer, BioNTech’s long-standing vaccine partner, has arranged to take over the production of the Covid-19 shot as BioNTech exits large-scale manufacturing in Germany.
What are the trial results for BioNTech’s oncology candidate gotistobart?
Data from the PRESERVE-003 trial showed a median overall survival of 18.5 months in patients with previously treated squamous non-small cell lung cancer, compared to 10.0 months on standard chemotherapy.